Second-line chemotherapy in patients with primary unknown cancerONO, Makiko; ANDO, Masashi; YONEMORI, Kan et al.Journal of cancer research and clinical oncology. 2011, Vol 137, Num 8, pp 1185-1191, issn 0171-5216, 7 p.Article

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?GRONLUND, B; HANSEN, H. H; HØGDALL, C et al.British journal of cancer. 2004, Vol 90, Num 2, pp 377-382, issn 0007-0920, 6 p.Article

Improving second-line therapy in aggressive non-Hodgkin's lymphomaGISSELBRECHT, Christian; MOUNIER, Nicolas.Seminars in oncology. 2004, Vol 31, pp 12-16, issn 0093-7754, 5 p., SUP2Article

How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatmentGHANIMA, Waleed; GODEAU, Bertrand; CINES, Douglas B et al.Blood. 2012, Vol 120, Num 5, pp 960-969, issn 0006-4971, 10 p.Article

A Review of Second- line Chemotherapy and Prognostic Models for Disseminated Germ Cell TumorsVOSS, Martin H; FELDMAN, Darren R; BOSL, George J et al.Hematology/oncology clinics of North America. 2011, Vol 25, Num 3, issn 0889-8588, viii-ix, 557-576 [22 p.]Article

A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research GroupKONTOPODIS, Emmanouil; HATZIDAKI, Dora; VARTHALITIS, Ioannis et al.Journal of chemotherapy (Testo stampato). 2013, Vol 25, Num 1, pp 49-55, issn 1120-009X, 7 p.Article

A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancerSEHOULI, Jalid; CAMARA, Oumar; MAHNER, Sven et al.Cancer chemotherapy and pharmacology. 2010, Vol 66, Num 5, pp 861-868, issn 0344-5704, 8 p.Article

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patientsHOCHHAUS, Andreas; KANTARJIAN, Hagop.Journal of cancer research and clinical oncology. 2013, Vol 139, Num 12, pp 1971-1984, issn 0171-5216, 14 p.Article

Phase II study of weekly paclitaxel in Patients with non-small cell lung cancer who have failed previous treatmentsYASUDA, Kazuhito; IGISHI, Tadashi; YAMAMOTO, Mistunobu et al.Oncology. 2004, Vol 66, Num 5, pp 347-352, issn 0030-2414, 6 p.Article

Extracorporeal photochemotherapy as second- or first-line therapy of acute GVHD?MERTIN, E; PAILLARD, C; ROCHETTE, E et al.Bone marrow transplantation (Basingstoke). 2010, Vol 45, Num 5, pp 963-965, issn 0268-3369, 3 p.Article

Second-line treatment of patients with metastatic colorectal cancerROUGIER, Philippe; LEPERE, Celine.Seminars in oncology. 2005, Vol 32, Num 6, issn 0093-7754, S48-S54, SUP9Conference Paper

Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group reportCREUTZIG, U; ZIMMERMANN, M; STARY, J et al.Leukemia. 2012, Vol 26, Num 4, pp 654-661, issn 0887-6924, 8 p.Article

Current Management of Pyogenic Liver Abscess: Surgery is Now Second-Line TreatmentMEZHIR, James J; FONG, Yuman; JACKS, Lindsay M et al.Journal of the American College of Surgeons. 2010, Vol 210, Num 6, pp 975-983, issn 1072-7515, 9 p.Article

Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South AfricaLEVISON, Julie H; ORRELL, Catherine; LOSINA, Elena et al.Antiviral therapy (London). 2011, Vol 16, Num 6, pp 853-861, issn 1359-6535, 9 p.Article

Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?JABBOUR, Elias; KANTARJIAN, Hagop M; O'BRIEN, Susan et al.Journal of clinical oncology. 2011, Vol 29, Num 32, pp 4260-4265, issn 0732-183X, 6 p.Article

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line TherapyROSINA THALLINGER, Christiane Maria; RADERER, Markus; HEJNA, Michael et al.Journal of clinical oncology. 2011, Vol 29, Num 35, pp 4709-4714, issn 0732-183X, 6 p.Article

Hypertension artérielle : traitement de deuxième ligne : D'autres monothérapies = Arterial hypertension and second choice therapiesLa Revue Prescrire. 2008, Vol 28, Num 293, pp 196-198, issn 0247-7750, 3 p.Article

The Importance of Patient Participation in Second-Line Chemotherapy Decisions : Perspectives of African-American PatientsPHIPPS, Etienne; MADISON, Nora; POLANSKY, Marcia et al.Journal of the National Medical Association. 2008, Vol 100, Num 12, pp 1434-1440, issn 0027-9684, 7 p.Article

A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication)MARIN, Alicia C; MCNICHOLL, Adrian G; GISBERT, Javier P et al.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 7, pp 843-861, issn 1465-6566, 19 p.Article

Clinical and Molecular Determinants of Survival in Pancreatic Cancer Patients Treated with Second-line Chemotherapy: Results of an Italian/Swiss Multicenter SurveyMANCUSO, A; SACCHETTA, S; RECINE, F et al.Anticancer research. 2010, Vol 30, Num 10, pp 4289-4295, issn 0250-7005, 7 p.Article

Phase II Study of Weekly Paclitaxel as a Second-line Treatment for S-1-refractory Advanced Gastric CancerMATSUDA, Goro; KUNISAKI, Chikara; KOSAKA, Takashi et al.Anticancer research. 2009, Vol 29, Num 7, pp 2863-2867, issn 0250-7005, 5 p.Article

Pegylated Liposomal Doxorubicin as Second-line Therapy in the Treatment of Patients With Advanced Classic Kaposi Sarcoma : A Retrospective StudyDI LORENZO, Giuseppe; DI TROLIO, Rossella; MONTESARCHIO, Vincenzo et al.Cancer. 2008, Vol 112, Num 5, pp 1147-1152, issn 0008-543X, 6 p.Article

A Combined Therapy with Docetaxel and Nedaplatin for Relapsed and Metastatic Esophageal CarcinomaMATSUMOTO, Hideo; HIRABAYASHI, Yoko; KUBOTA, Hisako et al.Anticancer research. 2012, Vol 32, Num 5, pp 1827-1831, issn 0250-7005, 5 p., aArticle

Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancerMANEGOLD, Christian; VANSTEENKISTE, Johan; CARDENAL, Felipe et al.Investigational new drugs. 2013, Vol 31, Num 1, pp 175-182, issn 0167-6997, 8 p.Article

Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancerHÜTTER, G; SZELENYI, H; DECKERT, P. M et al.Cancer chemotherapy and pharmacology. 2004, Vol 54, Num 2, pp 178-184, issn 0344-5704, 7 p.Article